Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Identification of novel viral entry factors and development of antiviral approaches

Project description

New strategies to stop emerging viruses

One way to prevent infectious diseases is to stop viruses from entering and replicating in target cells. The EU-funded DEFENDER project develops innovative antiviral strategies against (re-)emerging viruses by combining two complementary approaches: analysing how viruses interact with human cells and studying viral surface proteins that enable infection. Using advanced genetic and computational tools, the project aims to identify key human and viral targets for intervention. This knowledge will be used to develop new antiviral candidates, improve therapeutic antibodies and design next-generation vaccines. DEFENDER focuses on high-risk viruses such as Nipah, Lassa, Zika, dengue, yellow fever and chikungunya, aiming to strengthen preparedness and expand treatment options against future outbreaks.

Objective

DEFENDER will address the need for innovative intervention strategies against viruses with epidemic potential, by adopting a comprehensive and integrative platform approach. DEFENDER’s revolutionary Research and Innovation pipeline will focus on preventing virus entry through a host-directed bottom-up approach based on functional genetics in parallel to a top-down virus glycoprotein-centered approach. We will identify novel host dependency and restriction factors, including receptors and proteins involved in viral attachment and binding, endosomal uptake and virus genome uncoating, as targets for antiviral therapy. In parallel, we will use recombinant viral glycoproteins to identify broadly neutralizing nanobodies and novel epitopes for the AI-based design of next generation immunogens and the improvement of therapeutic antibodies. The host bottom-up functional genetic approach will be applied to Nipah, Lassa, Zika, Dengue, Yellow fever, and Chikungunya viruses. Host factors will be identified using a unique arrayed CRISPR perturbation platform, combined with advanced statistical and machine learning approaches and mathematical modelling, mechanistic experiments, and cutting-edge imaging techniques. In parallel, the virus top-down glycoprotein-centered approach will lead to the identification and structural characterization of broadly neutralizing nanobodies targeting conserved epitopes of the glycoproteins of Nipah and Lassa viruses in pre-fusion conformation. DEFENDER will deliver innovative antiviral candidates that induce target degradation, next generation immunogens, and a novel concept to improve the activity of therapeutic antibodies, with proof-of-concept preclinical evaluation in mice. It will define the most vulnerable virus-host interactions, to deliver a robust development pipeline for novel antivirals, therapeutic antibodies, and immunogens and increase antiviral options against a wide range of priority (re-) emerging viruses.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-RIA - HORIZON Research and Innovation Actions

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-HLTH-2024-DISEASE-08

See all projects funded under this call

Coordinator

LEIBNIZ-INSTITUT FUR VIROLOGIE
Net EU contribution
€ 1 303 431,25
Address
MARTINISTRASSE 52
20251 HAMBURG
Germany
Region
Hamburg Hamburg Hamburg
Activity type
Research Organisations
Links
Total cost
€ 1 303 431,25

Participants (9)

Partners (2)